Do not be misguided by guidelines: the calcium x phosphate product can be a Trojan horse.

dialysis adequacy and nutritional indices for mortality and morbidity in CAPD and HD patients. A longitudinal study. Nephrol Dial Transplant 1995; 10: 2295–2305 4. Diaz-Buxo J, Lowrie E, Lew N et al. Associates of mortality among peritoneal dialysis patients with special reference to peritoneal transport rates and solute clearance. Am J Kidney Dis 1999; 33: 523–534 5. Szeto C-C, Wong T, Leung C et al. Importance of dialysis adequacy in mortality and morbidity of Chinese CAPD patients. Kidney Int 2000; 58: 400–407 6. Jansen M, Hart A, Korevaar J, Dekker F, Boeschoten E, Krediet R. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int 2002; 62: 1046–1053 7. Rocco M, Soucie J, Pastan S, McClellan W. Peritoneal dialysis adequacy and risk of death. Kidney Int 2000; 58: 446–457 8. Churchill D, Taylor D, Keshaviah P for the CANUSA Peritoneal Dialysis Study Group. Adequacy of dialysis and nutrition in continuous peritoneal dialysis. Association with clinical outcomes. J Am Soc Nephrol 1996; 7: 198–207 9. Bargman J, Thorpe K, Churchill D. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001; 12: 2158–2162 10. Suda T, Hiroshige K, Ohta T et al. The contribution of residual renal function to overall nutritional status in chronic haemodialysis patients. Nephrol Dial Transplant 2000; 15: 396–401 11. Shemin D, Bostom A, Laliberty P, Dworkin L. Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis 2001; 38: 85–90 12. Moist L, Port F, Orzol S et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 2000; 11: 556–564 13. Bammens B, Evenpoel P, Verbeke K, Vanrenterghem Y. Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int 2003; 64: 2238–2243 14. Menon M, Naimark D, Bargman J, Vas S, Oreopoulos D. Long-term blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function. Nephrol Dial Transplant 2001; 16: 2207–2213 15. Ates K, Nergizoglu G, Keven K et al. Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. Kidney Int 2001; 60: 767–776 16. Konings C, Kooman J, Schonck M et al. Fluid status in CAPD patients is related to peritoneal transport and residual renal function: evidence from a longitudinal study. Nephrol Dial Transplant 2003; 18: 797–803 17. Wang A, Wang M, Woo J et al. A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients. Kidney Int 2002; 62: 639–647 18. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154–2169 19. Misra M, Vonesh E, Churchill D, Moore H, Van Stone J, Nolph K. Preservation of glomerular filtration rate on dialysis when adjusted for patient dropout. Kidney Int 2000; 57: 691–696 20. Van Biesen W, Vanholder R, Veys N, Dhondt A, Lameire N. An evaluation of an integrative care approach for end-stage renal disease patients. J Am Soc Nephrol 2000; 11: 116–125 21. Baker R, Senior H, Clemenger M, Brown E. Empirical aminoglycosides for peritonitis do not affect residual renal function. Am J Kidney Dis 2003; 41: 670–675 22. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343: 180–184 23. Van Olden R, Guchelaar H, Struijk D, Krediet R, Arisz L. Acute effects of high-dose furosemide on residual renal function in CAPD patients. Perit Dial Int 2003; 23: 339–347. 24. Medcalf J, Harris K, Walls J. Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int 2001; 59: 1128–1133 25. Jassal S, Lok C, Walele A, Bargman J. Continued transplant immunosuppression may prolong survival after return to peritoneal dialysis: results of a decision analysis. Am J Kidney Dis 2002; 40: 178–183 26. Li P, Chow K-M, Wong T, Leung C-B, Szeto C-C. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. Ann Intern Med 2003; 139: 105–112 27. Suzuki H, Kanno Y, Sugahara S, Okada H, Nakamoto H. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis 2004; 43: 1056–1064